NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study
Evaluation of a Pragmatic NT-ProBNP-based Heart Failure Screening Strategy Among Patients With Type 2 Diabetes: STRONG-DM Study (Screening and Treatment Using Risk-based apprOach With NT-ProBNP Guidance in Diabetes Mellitus
- Type 2 Diabetes
- Diabetic Cardiomyopathy
- Heart Failure
- Cardiometabolic Diseases
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- University of Texas Southwestern Medical Center
- Enrolment target
- 300
- Started
- 10 February 2025
- Main results due
- 10 December 2027
- Study sites
- 3
- Registry updated
- 29 September 2026
Can you take part?
- No age limit is stated.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Primary Care Provider that sees diabetes patients in clinic Exclusion Criteria: * Provider does not see patients with Diabetes
What this study is about
In the sponsor’s own words, from the registry.
A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a clinical decision support tool to implement an intensive prevention strategy among patients with high risk focused on implementation of evidence-based HF preventive therapies.
Study sites(3)
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Recruiting
Parkland Health & Hospital System (PHHS)
Dallas, Texas, United States
Recruiting
Baylor Scott and White - Health System
Dallas, Texas, United States
Recruiting
Showing 3 of 3 sites. 3 of the 3 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06593327. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me